BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

In the latest quarter, 15 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing ...

Atomi Financial Group Inc. bought a new position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) during the 3rd quarter, ...

Truist Financial Corp lowered its position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 4.1% in the second quarter ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...

Shares of NASDAQ BNTX opened at $117.47 on Monday. The business has a 50-day simple moving average of $99.38 and a two-hundred day simple moving average of $92.98. BioNTech has a 52 week low of ...

Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) ...

Shares in Novavax (NASDAQ:NVAX) slumped in premarket US trading on Wednesday after the US Food and Drug Administration placed ...

We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a ...